MRNA — All updates

We view Moderna as a "sell" product. Citigroup gave it a "sell" rating today. This comes after Moderna's recent strong performance, thanks to some positive trial results . They have downgraded its rating to "Sell" from " Neutral".

At the same time, they raised the target price for the stock, but only to 80. This is a rise from 60. So, their outlook wasn't very positive before today. This means a potential drop of more than 60% from yesterday's closing levels.

there is a question from one of our viewers. He asked what you think of mRNA and how this bull flag originated. Do you think there will be a continuation, or do you think the momentum will slowly fade?

I look at it and say that no one can predict where the momentum will fade. So instead, I look at it and say: look at the 30-minute timeframe, and it is innocent until proven guilty.

It moves along with this rising 5-day moving average. So I would say that you should look at the most recent relevant higher low above that 5-day moving average. So I think that if we break through the 190, the most likely scenario for mRNA is that it does something like this: maybe we start to divide, break through that lower bottom here, see a lower top, get stuck below the 5-day average, and then maybe pull back a bit towards the 175, and then it is ready to rise again.

AMJ Wellness Matters is mentioning Madna. We talked about that a little bit earlier. Let's see how that's resolved here. 190s. This kept trading. Oh man, Madna all green candles both buying or excuse me both price and volume.

Yeah, this is um this a really nice resolution of a bull penant uh formation that we had that started uh back in August when we got that news of I forget exactly what the news was, but is I think that regarding using AI personalized mRNA vaccines for things like cancer and stuff.

The first arrow, literally in the 99.9 percentile, is Moderna, its code is MRNA. Clearly, this name has become familiar to many of us during the COVID-19 pandemic. Moderna and Pfizer were key names to watch.

But look how this stock rebounded in 2026, and how its rise has accelerated remarkably in the recent period. Six weeks. A large price gap to the upside occurred in mid-August following the approval of a drug, and prices have since consolidated.

MRNA is going to be next here. Bigab is mentioning that this is rolling here today. Like we had what an 11 point move here on Madna. 14 10% move here. Look at Madna ripping out of the gate here.

Wait a minute. I got to look at this cuz we talked about how this was breaking out of consolidation. It was bull flagging and or bull penant and here we are. We are moving up. Uh looks like what is it 175?

So the high was 1766. Uh I mean to me this looks like we're getting a resolution of this bullish pattern here. And uh that means we'll probably end up seeing 180 maybe more.

Uh Madna up 10 plus percent here today. And look at this. This also breaking out of this structure. Now, I know we talk a lot about islands here. There's definitely price history to the left.

So, that's one thing. We never actually came back into the bottom of this candle, but boy oh boy, this 130 looked like some pretty good support. Now it actually looks like your next target here might be 176. That's Madna MRNA.

And speaking of healthcare, Stefan was asking earlier about Madna, which obviously had the huge cancer vaccine news. Here's a look at the chart 13. I know we're running out of time, but to me, this really kind of needs to hold 130.

1301 120. If it holds these two areas, we still have room in this God candle that we're still inside to the upside. But if we end up coughing this up, I think we are looking at a nasty gap fill below.

So then uh you've got Mona coming down again a little bit here. another 8%. There is a lot of trading volume in this. So, it's not uncommon to see some of this juice come out. This is a very very normal kind of post enthusiasm bleed out.

Uh, and I'm very curious to see if it stabilizes at 126 or if it keeps going down. Uh, could be some opportunities there. Obviously, the company still loses money, but massive hope and it's not really a cancer vaccine.

I know people call it a cancer vaccine, but it's more of um a cancer therapy that they're working on, which which is also very important. Um in fact, um I mean, while a vaccine would be cool, I think this is more of a first stage.